COMPANY

Orlance

HQ: Seattle, WA source · orlance.com ↗ · West Coast

Our platform enables rapid vaccine production without cold chain requirements, leveraging $16.8M in NIH SBIR funding to advance DNA and RNA vaccines toward Phase 1 clinical trials. The company is raising a $12M Series A in 2026 and seeking partners to develop an expanded portfolio of vaccine and immunotherapy assets. From company website Source · Oct 13, 2026

Keywords: clinical trials vaccines sbir immunotherapy

Location: Seattle, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

18NIH grants

Funding and NIH signals

NIH award NIH awarded $1M (SBIR Phase II 4R44AI186932-02, extension, notice Aug 31, 2026); 2 NIH awards totaling $1.3M in the last 12 months. NIH RePORTER 4R44AI186932-02 (Aug 31, 2026)
Evidence (2 events)
- Aug 31, 2026 · NIH RePORTER 4R44AI186932-02
  Organization: ORLANCE, INC.; City/State: SEATTLE, WA; Project number: 4R44AI186932-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens; Organization type: Domestic For-Profits
- Aug 14, 2026 · NIH RePORTER 5R41AI195068-02
  Organization: ORLANCE, INC.; City/State: SEATTLE, WA; Project number: 5R41AI195068-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 298837; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Therapeutic nucleic acid vaccine for chronic hepatitis B in HIV/HBV co-infected individuals; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Aug 31, 2026 Grant Government grant — SBIR: $1M (annual award, as published), announced Aug 31, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 14, 2026 Grant Government grant — STTR: $298,837 (annual award, as published), announced Aug 14, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Sep 11, 2025 Grant Government grant — STTR: $300,000 (annual award, as published), announced Sep 11, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 19, 2025 Grant Government grant — SBIR: $977,255 (annual award, as published), announced Aug 19, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 17, 2025 Grant Government grant — SBIR: $300,000 (annual award, as published), announced Apr 17, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Aug 31, 2026 Government grant — SBIR: $1M (annual award, as published), announced Aug 31, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 14, 2026 Government grant — STTR: $298,837 (annual award, as published), announced Aug 14, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Sep 11, 2025 Government grant — STTR: $300,000 (annual award, as published), announced Sep 11, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 19, 2025 Government grant — SBIR: $977,255 (annual award, as published), announced Aug 19, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 17, 2025 Government grant — SBIR: $300,000 (annual award, as published), announced Apr 17, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 18

Annual award amounts. Total $12.3M.

Aug 13, 2024 NIH award 5R44AI179440-02 FY2024: $990,275 awarded for that fiscal year; activity R44 (SBIR); PI FRIZZELL, HANNAH; recipient as written: ORLANCE, INC., SEATTLE, WA. Clinic-Ready MACH-1 Gene Gun for delivery of a univ source ↗
Aug 8, 2024 NIH award 1R44AI186932-01 FY2024: $300,000 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Enhanced Seasonal Influenza Vaccine Targeting Vari source ↗
Aug 1, 2024 NIH award 5R43CA281585-02 FY2024: $200,000 awarded for that fiscal year; activity R43 (SBIR); PI FRIZZELL, HANNAH; recipient as written: ORLANCE, INC., SEATTLE, WA. Next Generation Gene-Gun Delivered DNA and RNA Immu source ↗
May 3, 2024 NIH award 1R43AI181303-01A1 FY2024: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI FRIZZELL, HANNAH; recipient as written: ORLANCE, INC., SEATTLE, WA. Gene Gun-delivered RNA vaccines. source ↗
Apr 30, 2024 NIH award 5R44AI153011-04 FY2024: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Universal Influenza A/B Vaccine source ↗
Sep 21, 2023 NIH award 1R43CA281585-01A1 FY2023: $200,000 awarded for that fiscal year; activity R43 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Next Generation Gene-Gun Delivered DNA and RNA I source ↗
Aug 21, 2023 NIH award 1R44AI179440-01 FY2023: $996,500 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Clinic-Ready MACH-1 Gene Gun for delivery of a uni source ↗
May 23, 2023 NIH award 5R44AI153011-03 FY2023: $998,889 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Universal Influenza A/B Vaccine source ↗
May 3, 2022 NIH award 4R44AI153011-02 FY2022: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Universal Influenza A/B Vaccine source ↗
May 6, 2021 NIH award 3R44AI122371-05S1 FY2021: $955,395 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Development of a rapid response nucleic acid vac source ↗
Apr 30, 2021 NIH award 5R44AI122371-05 FY2021: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. DNA prime / rVSV boost Multi-Antigen Universal I source ↗
Aug 7, 2020 NIH award 1R44AI153011-01A1 FY2020: $300,000 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Universal Influenza A/B Vaccine source ↗
Jun 2, 2020 NIH award 3R44AI122371-04S1 FY2020: $908,934 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Development of a rapid response nucleic acid vac source ↗
Apr 9, 2020 NIH award 5R44AI122371-04 FY2020: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. DNA prime / rVSV boost Multi-Antigen Universal I source ↗
Aug 23, 2019 NIH award 7R44AI114331-03 FY2019: $569,505 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. Optimization of an innate immune stimulating adjuv source ↗
Aug 16, 2019 NIH award 7R44AI122371-03 FY2019: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI BAGLEY, KENNETH C; recipient as written: ORLANCE, INC., SEATTLE, WA. DNA prime / rVSV boost Multi-Antigen Universal I source ↗
Mar 4, 2019 NIH award 5R43AI140784-02 FY2019: $298,613 awarded for that fiscal year; activity R43 (SBIR); PI AALTO, KRISTYN RENE; recipient as written: ORLANCE, INC., SEATTLE, WA. Design and Optimization of Clinical Gene Gun for source ↗
Apr 10, 2018 NIH award 1R43AI140784-01 FY2018: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI MUNSON, PAUL VENESS; recipient as written: ORLANCE, INC., SEATTLE, WA. Design and Optimization of Clinical Gene Gun for source ↗